Table 14.8

De Novo Post Transplant Solid Malignancy, 1997 to 2006

Liver Recipients

Malignancies by Type Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total # of Post-Tx Malignancies 272 287 277 207 201 206 146 156 133 49
Squamous/Basal Cell Carcinoma 110 109 105 86 76 73 47 48 44 12
Melanoma 9 5 13 2 3 6 4 2 10 4
Kaposi Sarcoma - - 5 2 1 2 - 1 - -
Central Nervous System 1 5 - 1 3 2 1 2 - 1
Genito-Urinary (1) 27 37 20 24 21 12 14 11 7 5
Gastro-Intestinal (2) 38 42 37 21 24 15 18 16 14 6
Primary Hepatic Tumor 5 13 12 13 7 16 10 12 14 2
Metastatic Hepatic Tumor 9 12 5 7 10 14 11 10 11 5
Larynx/Bronchi/Lung 36 42 38 27 32 35 18 31 16 7
Breast/Thyroid 13 5 15 5 8 9 5 6 6 3
Leukemia 3 3 - - 1 2 3 3 1 -
Sarcoma (3) - - 1 1 - 2 3 2 1 -
Other 14 11 17 15 9 16 10 9 8 4
Unknown 7 3 9 3 6 2 2 3 1 -
Squamous/Basal Cell Carcinoma 40.4% 38.0% 37.9% 41.5% 37.8% 35.4% 32.2% 30.8% 33.1% 24.5%
Melanoma 3.3% 1.7% 4.7% 1.0% 1.5% 2.9% 2.7% 1.3% 7.5% 8.2%
Kaposi Sarcoma - - 1.8% 1.0% 0.5% 1.0% - 0.6% - -
Central Nervous System 0.4% 1.7% - 0.5% 1.5% 1.0% 0.7% 1.3% - 2.0%
Genito-Urinary (1) 9.9% 12.9% 7.2% 11.6% 10.4% 5.8% 9.6% 7.1% 5.3% 10.2%
Gastro-Intestinal (2) 14.0% 14.6% 13.4% 10.1% 11.9% 7.3% 12.3% 10.3% 10.5% 12.2%
Primary Hepatic Tumor 1.8% 4.5% 4.3% 6.3% 3.5% 7.8% 6.8% 7.7% 10.5% 4.1%
Metastatic Hepatic Tumor 3.3% 4.2% 1.8% 3.4% 5.0% 6.8% 7.5% 6.4% 8.3% 10.2%
Larynx/Bronchi/Lung 13.2% 14.6% 13.7% 13.0% 15.9% 17.0% 12.3% 19.9% 12.0% 14.3%
Breast/Thyroid 4.8% 1.7% 5.4% 2.4% 4.0% 4.4% 3.4% 3.8% 4.5% 6.1%
Leukemia 1.1% 1.0% - - 0.5% 1.0% 2.1% 1.9% 0.8% -
Sarcoma (3) - - 0.4% 0.5% - 1.0% 2.1% 1.3% 0.8% -
Other 5.1% 3.8% 6.1% 7.2% 4.5% 7.8% 6.8% 5.8% 6.0% 8.2%
Unknown 2.6% 1.0% 3.2% 1.4% 3.0% 1.0% 1.4% 1.9% 0.8% -
Total # of Patients 200 208 207 171 161 168 124 125 102 42


Source: OPTN/SRTR Data as of May 1, 2007.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.